Home / Market News / $OSCR
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Piper Sandler Maintains Overweight Rating on Oscar Health, Lowers Price Target to $45

Nov 6, 2026, 7:10 PM UTC · Primary ticker $OSCR

Piper Sandler maintained its 'Overweight' rating on Oscar Health but reduced its price target from $48 to $45. This indicates a slightly less optimistic outlook on the stock's near-term valuation, despite the continued positive recommendation.

Piper Sandler reaffirmed its 'Overweight' rating on Oscar Health, signaling continued confidence in the company's long-term prospects. However, the simultaneous reduction of the price target from $48 to $45 suggests a recalibration of near-term valuation expectations, possibly due to market conditions or updated financial models. This action primarily affects Oscar Health (OSCR) shareholders, as it could lead to some short-term selling pressure or temper bullish sentiment. In the long term, the maintained 'Overweight' rating still implies potential upside, but the lowered target indicates a more conservative growth trajectory. A key risk for traders is that other analysts might follow suit with similar price target reductions, while an opportunity lies in the potential for the stock to rebound if Oscar Health outperforms expectations or market sentiment improves.

$OSCR negative Price target lowered
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.